This Pill Kills Tumors — Scientific Breakthrough Just Got Us Closer to Curing Cancer

Revolutionizing Cancer Treatment: The Remarkable Impact of the Tumor-Eliminating Pill

In 2022, the world was taken by storm as a clinical study of Dostarlimab successfully cured all 12 patients of rectal cancer. Now, just over a year later, scientists have successfully made more incredible leaps toward making cancer survivable. As the exciting field of oncology marches on the innovations being made are fascinating — and have incredible potential for reshaping the survivability of cancers.

Osimertinib and The University Trial at Yale

Yale reported that a trial showed significant success in lowering the risk of patients dying from lung cancer in early 2023. This trial, called the Adaura trial, is the culmination of decades of research across over 20 countries. The results of the late-stage study, led by Yale University, reduced the risk of patients dying — by a whopping 51%. According to Yale,

“After five years, 88% of patients who took the daily pill after the removal of their tumor were still alive, compared with 78% of patients treated with a placebo. Overall, there was a 51% lower risk of death for those who received osimertinib compared…